Arizona joins 14 other states in requiring breast density patient notification.
Arizona became the 15th state to pass a breast density patient notification law yesterday.
Governor Jan Brewer signed the bill, which will become effective October 1. The law requires that a health care institution or facility that categorizes a patient as having heterogeneously dense or extremely dense breasts based on breast image reporting and the data system established by the American College of Radiology must include the following in the summary of the mammography report sent to the patient:
Your mammogram indicates that you have dense breast tissue. Dense breast tissue is common and is found in fifty percent of women. However, dense breast tissue can make it more difficult to detect cancers in the breast by mammography and may also be associated with an increased risk of breast cancer. This information is being provided to raise your awareness and to encourage you to discuss with your health care providers your dense breast tissue and other breast cancer risk factors. Together, you and your physician can decide if additional screening options are right for you. A report of your results was sent to your physician.
According to the Are You Dense? Advocacy group, breast density predicts the accuracy of mammographic screening, and utilizing adjuvant breast screening tools can increase detection of early stage breast cancer for women with dense breast tissue up to 100 percent. The group also states that breast density is one of the strongest risk factors associated with breast cancer.
A federal density reporting bill, the Breast Density and Mammography Reporting Act, was introduced to the U.S. House of Representatives in October 2013. It was referred to the Subcommittee on Health in November 2013.
An informal reader poll by Diagnostic Imaging in April 2012 indicated that 75 percent of respondents were in favor of the inclusion of breast density information in the mammography summary letter sent to patients.
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.
FDA Clears Updated AI Platform for Digital Breast Tomosynthesis
November 12th 2024Employing advanced deep learning convolutional neural networks, ProFound Detection Version 4.0 reportedly offers a 50 percent improvement in detecting cancer in dense breasts in comparison to the previous version of the software.